Canaccord Genuity Maintains Buy on Exagen, Lowers Price Target to $9

Benzinga · 4d ago
Canaccord Genuity analyst Kyle Mikson maintains Exagen (NASDAQ:XGN) with a Buy and lowers the price target from $11 to $9.